PT  - JOURNAL ARTICLE
AU  - ANTOINE MICHAEL SAAB
AU  - MICHAEL DOBMEIER
AU  - BURKHARD KOENIG
AU  - ENRICA FABRI
AU  - ALESSIA FINOTTI
AU  - MONICA BORGATTI
AU  - ILARIA LAMPRONTI
AU  - FRANCESCO BERNARDI
AU  - THOMAS EFFERTH
AU  - ROBERTO GAMBARI
TI  - Antiproliferative and Erythroid Differentiation of Piperazine and Triphenyl Derivatives Against K-562 Human Chronic Myelogenous Leukemia
DP  - 2013 Aug 01
TA  - Anticancer Research
PG  - 3027--3032
VI  - 33
IP  - 8
4099  - http://ar.iiarjournals.org/content/33/8/3027.short
4100  - http://ar.iiarjournals.org/content/33/8/3027.full
SO  - Anticancer Res2013 Aug 01; 33
AB  - Five piperazine derivatives (S)-4-benzyl-1-(4-bromo-3-methylphenyl)-2 methylpiperazine (A), (S)-1-benzyl-3-isobutylpiperazine-2,5-dione (B), (S)-1-benzyl-3 methylpiperazine-2,5-dione (C), (S)-1,3-dibenzylpiperazine-2,5-dione (D), (E)-1-(3-methyl 4-((E)-3-(2-methylpropylidene) piperazin-1-yl) phenyl)-2-(2 methylpropylidene) piperazine (E) and triphenyl derivative ammonium 2-((2,3’,3’‘-trimethyl-[1,1’:4’,1’‘-terphenyl]-4 yl)oxy)acetate (F) were tested for inhibition of K-562 cell proliferation and for induction of erythroid differentiation. Among them, two piperazine and one triphenyl derivatives, compounds A, E, and F inhibited the proliferation of the K562 cell lines exhibiting inhibition concentration 50 (IC50) (IC50) of values 30.10±1.6, 4.60±0.4 and 25.70±1.10 μg ml−1, respectively. If compound A and F were added to suboptimal concentrations of the established anticancer drugs cytosine arabinoside or mithramycin, pronounced synergic effects were observed.